Analysis of differentiation of antiEGFR antibody in the 1st line chemotherapy with mFOLFOX6 in RAS-wild metastatic colorectal cancer.
Phase 4
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000031535
- Lead Sponsor
- Kyoto Katsura Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
severe dysfunctions of vital organs no prior radiotherapy, chemotherapy no other co-existing malignancy within the last five years no severe concurrent medical or psychiatric illnessno hypersensitivity to the study drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method safety relapse-free survival overall survival early tumor shurinkage neutrophil to lymphocyte ratio